Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$0.49 ▼ -0.05
(-9.43%)
MKT CAP: $120.1M • VOL: 7.06M
52W L $0 52W H $3
ROARABLE / RQD
D- • 38/100
PIOTROSKI
2 / 9
OTLK // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-09-30 | FY 2024
FILED 2024-09-30 | FY 2023
FILED 2023-09-30 |
|---|---|---|---|
| Revenue (Total Sales) | $1.4M | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | $57.2K | — | — |
| Gross Margin % | 4.0% | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$67.1M | -$71.7M | -$53.1M |
| Operating Margin % | -80.0% | — | — |
| Net Income (GAAP) | -$62.4M | -$75.4M | -$59.0M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$51.8M | -$68.8M | -$43.0M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$51.8M | -$68.8M | -$43.0M |
| FCF Margin % | -80.0% | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $8.7M | $5.7M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | -$38.5M | -$50.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR OTLK.